In a business merger agreement, Takeda‘s wholly-owned subsidiary, Takeda America Holdings, will acquire LigoCyte for an upfront payment of $60 million, with future contingent consideration based on the progress of development projects.
LigoCyte is a privately-held biopharmaceutical company specializing in innovative vaccine products headquartered in Bozeman, Montana.
“Takeda’s acquisition of LigoCyte is a major step forward in the expansion of Takeda’s vaccine business, and a demonstration of Takeda’s dedication to preventing illness in children and adults around the world,” said Rajeev Venkayya, M.D., executive vice president of Takeda’s Vaccine Business Division (VBD), which was launched in January 2012.
With this business merger Takeda foresees to change the picture of gastroenteritis and other food borne illnesses around the world, through the revolutionary norovirus vaccine
For further deal information visit Current Agreements (subscription required)
Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Merger and Acquisition Terms and Agreements
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity